$1.25+0.01 (+0.81%)
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases.
Telomir Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.25 with a market capitalization of $86M. The stock is currently near its 52-week low of $1.05, remaining 7.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | β | β | β | β | β |
| Operating Income | -$1.04Mβ | -$2.13Mβ | -$1.15Mβ | -$5.07Mβ | -$2.19M |
| Net Income | -$990,947β | -$2.06Mβ | -$1.10Mβ | -$5.07Mβ | -$2.18M |
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral...
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) and the actively traded Invesco Q
td class="col-issue">Next Technology Holding Inc.